Oculis Reports Positive Phase 2 Data for Privosegtor
Oculis reported positive Phase 2 data for privosegtor in optic neuritis.
Related stories
Carrier Q3 Revenue $6.3 Billion
M impact | EQUITY | Oct 29, 2026, 10:02 AM UTC
Ares Raises $31 Billion in Third-Quarter Fundraising
Ares Management raised $31 billion in the third quarter, driven by strength across private credit, real estate and infrastructure businesses.
M impact | EQUITY | Oct 29, 2026, 10:02 AM UTC
Viking Therapeutics Reports $183.2 Million Third-Quarter Net Loss
The company reported no revenue and diluted loss per share of $1.55, compared with a $90.8 million net loss and $0.81 diluted loss per share a year earlier.
M impact | EQUITY | Oct 29, 2026, 10:02 AM UTC
Portland General Electric Reports Third-Quarter Revenue of $971 Million
Third-quarter 2026 revenue rose 2% year over year to $971 million, while net income increased 16% to $119 million. Retail revenue growth more than offset lower wholesale sales volu
M impact | EQUITY | Oct 29, 2026, 10:02 AM UTC
CRH launches share buyback of up to $6B
M impact | EQUITY | Oct 29, 2026, 10:02 AM UTC
Silgan Reports Third-Quarter Results, Raises Full-Year Earnings Estimate Midpoint
M impact | EQUITY | Oct 29, 2026, 10:02 AM UTC